Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Roginolisib, a first-of-its-kind PI3Kδ inhibitor, is showing early promise in metastatic uveal melanoma — a rare cancer with very few effective treatment options. Phase 1 data published in Nature Communications showed a median overall survival of 18.4 months in uveal melanoma patients, with a manageable safety profile. Developers are now eyeing randomized trials in uveal melanoma and non–small cell lung cancer.
Roginolisib, a conformation-selective PI3Kδ inhibitor, is showing early but meaningful promise in metastatic uveal melanoma — one of the rarest and most treatment-resistant cancers around. Data from a first-in-human phase 1 trial (NCT04328844), published in Nature Communications, revealed a median overall survival (OS) of 18.4 months in 27 uveal melanoma patients, with the broader efficacy-evaluable population (n = 40) achieving a median OS of 28.5 months at a median follow-up of 17.9 months.
The drug works by locking PI3Kδ in an inactive state — blocking the enzyme from being activated by ATP and cutting off a key cancer-signaling molecule. Patients took roginolisib orally once daily, with an 80 mg dose selected for expansion. Investigators specifically targeted uveal melanoma, cutaneous melanoma, and mesothelioma due to their known overexpression of PI3Kδ.
By the Numbers:
Why it matters: Uveal melanoma has historically lacked effective systemic therapies, making even modest survival gains significant. Roginolisib's favorable safety profile and durable OS data are encouraging enough that the company is advancing toward randomized trials — a meaningful step forward for patients with this devastating disease.
